Fact CheckerSign in

NCT04191824Completed

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

Source: ClinicalTrials.gov · Last updated 25 Mar 2026

Brief summary (registry, in English)

GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and provider (Intervention arm) versus delayed APOL1 gene testing and ROR to participant and provider (Control arm). The main study will compare outcomes between APOL1 positive participants in the Intervention arm (i.e., early knowledge of APOL1 status) to APOL1 positive participants in the Control arm (i.e., delayed knowledge of APOL1 status). Participants that are APOL1 negative in the Intervention and Control groups will not be included in the main study analyses. GUARDD-US also includes a substudy to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP from baseline to 3 months in APOL1 negative individuals at participating sites. This substudy is listed separately on clinicaltrials.gov as NCT06748040 and Unique Protocol ID - PRO00102997\_A

Status (registry)
Completed
Study type
Interventional
Enrollment
6789 (actual)
First submitted
5 Dec 2019
Start date
10 Jul 2020
Primary completion date
9 Apr 2024
Lead sponsor
Duke University
NCT number
NCT04191824

What you commit to

  • Study type: Interventional
  • Participants enrolled: 6789
  • From 10 Jul 2020 to the primary completion date, 9 Apr 2024
  • 14 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Are currently on dialysis (ICD 10 codes N18.6, Z99.2 and Z94.0)
  • Have had a liver, kidney, or allogeneic bone marrow transplant
  • Previously participated in the GUARDD pilot study OR have previously undergone APOL1 testing

Other illness

  • Have diabetes, but no CKD.
  • Have a terminal illness
  • Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility)
  • Not a current patient seeing a provider who cares for their hypertension (i.e., family medicine, internal medicine, nephrology, HIV provider, cardiology, hypertension specialists) at a participating site

Lab values

  • Have ESRD (eGFR\<15 ml/min)

Other

  • Have a left ventricular assist device (LVAD)
  • Have patient-reported known pregnancy at time of enrollment
  • Too cognitively impaired to provide informed consent and/or complete the study protocol
  • Plan to move out of the area within 6 months of enrollment

Who the study is looking for

  • Self reported African ancestry
  • English Speaking
  • Age 18-70 years
  • Have diagnosis of hypertension: Diagnosis of hypertension is defined by either:
    • ICD10 diagnosis codes (i.e., I10; I11.x; I12.x; I13.x; I16.x) OR
    • On active antihypertensive therapy for indication of hypertension OR
    • Having systolic blood pressure of 140 mm Hg or greater in at least 2 of the last 3 consecutive recorded values in the EHR OR
    • Having hypertension in the patient's medical record problem list
  • Have been seen at ≥1 time in past year at a participating primary care site
  • Either: 1) do not have diabetes and do not have CKD, or 2) have CKD; Participants with diabetes may be included as long as they also have CKD.
    • CKD is defined by either: A) ICD10 codes (i.e., N18.x; E08.22; E09.22; E10.22; E11.22;E13.22 (exclude Z94.0; N18.6; Z99.2)) OR B) Microalbumin/proteinuria level \>30 mg/g for 2 time periods ≥ 3 months. Values taken within 12 months of enrollment, unless 2 values are unavailable, then review within 24 months of enrollment. OR C) 15 ≤ eGFR ≤ 60 ml/min for 2 time periods ≥ 3 months. GFRs are taken within 12 months of enrollment, unless 2 values are unavailable, then review within 24 months.
    • Diabetes is defined by: HbA1c ≥ 6.5 at least one time in the last year OR ICD10 diagnosis codes OR Having diabetes in the patient's medical record problem list.

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (14)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Alabama at Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited StatesUnknown status
Baylor Research Institute
Coordinator of this site? Confirm its status
DallasUnited StatesUnknown status
University of Florida - Gainesville
Coordinator of this site? Confirm its status
GainesvilleUnited StatesUnknown status
Eskenazi Health
Coordinator of this site? Confirm its status
IndianapolisUnited StatesUnknown status
Indiana University
Coordinator of this site? Confirm its status
IndianapolisUnited StatesUnknown status
University of Florida - Jacksonville
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status
Southeastern Healthcare
Coordinator of this site? Confirm its status
LumbertonUnited StatesUnknown status
Vanderbilt University Medical Center
Coordinator of this site? Confirm its status
NashvilleUnited StatesUnknown status
Meharry Medical College
Coordinator of this site? Confirm its status
NashvilleUnited StatesUnknown status
Nashville General Hospital
Coordinator of this site? Confirm its status
NashvilleUnited StatesUnknown status
University Medical Center New Orleans
Coordinator of this site? Confirm its status
New OrleansUnited StatesUnknown status
The Institute for Family Health
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Icahn School of Medicine at Mount Sinai
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
University of Pittsburgh
Coordinator of this site? Confirm its status
PittsburghUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.